Expanded access to a new BCG vaccine for non-muscle invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial offers early access to a new form of the BCG vaccine (a treatment that helps your immune system fight bladder cancer) for people with non-muscle invasive bladder cancer. It may be an option if the standard vaccine is not available or has not worked for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (any age) with non-muscle invasive bladder cancer.
- If you have never had BCG treatment before, the standard BCG vaccine must be unavailable at your center.
- You must meet your doctor's standard criteria for using the TICE BCG vaccine, as outlined in its label.
- You must not have any condition that makes standard BCG unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This trial tests a personalized approach to using BCG immunotherapy for high-risk non-muscle-invasive bladder cancer. It aims to improve treatment response by tailoring the therapy based on your immune system.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.